Gyre Therapeutics

Gyre Therapeutics anticipates key data readouts in 2025 for F351, a novel anti-fibrotic therapy for CHB-associated liver fibrosis, currently in Phase 3 trials in China. Plans include a Phase 2 trial for MASH-associated liver fibrosis in the U.S. and advancing F573 and F230. Commercial launches of Avatrombopag maleate and Nintedanib in China are expected, adding to its portfolio. Q3 2024 revenues were $25.5M, with $15.9M cash supporting operations through 2025.

Gyre Therapeutics reported Q3 2024 revenue of $25.5M, down from $32.0M in Q3 2023, and net income of $2.9M, down from $7.5M. The company completed its Phase 3 trial for F351 in CHB-associated liver fibrosis, with data expected in Q1 2025. Planned commercial launches of avatrombopag and nintedanib are set for 2025, and preparations are underway for a U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis. Cash and equivalents stood at $15.9M as of September 30, 2024.

Gyre Therapeutics reports financial results for Q3 and 9 months ended Sept 30, 2024, with cash and cash equivalents of $15.9 million. The final patient completed the 52-week pivotal Phase 3 trial for F351 in CHB-associated liver fibrosis, with topline data expected Q1 2025. Plans include U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025, and commercial launches of avatrombopag and nintedanib in 2025.

Gyre Therapeutics announces completion of F351 Phase 3 trial for CHB-associated liver fibrosis in China, with topline data expected by Q1 2025. The trial, involving 248 patients, aims to reduce liver fibrosis using F351, a drug with anti-fibrotic effects in vitro and in vivo models. Gyre plans to initiate a Phase 2 trial in the U.S. for F351 in MASH-associated fibrosis in 2025.

Totus Medicines secured $66M in Series B funding led by DCVC Bio, with contributions from North Pond Ventures, Camford Capital, and the University of Minnesota. The funds will advance clinical programs, expand the pipeline, and evolve their AI-driven drug discovery platform. Nassim Usman, Ph.D., was appointed President & CEO, with Neil Dhawan, Ph.D., transitioning to CSO and Head of R&D.